Orion Infusion Limited (DSE:ORIONINFU)

Bangladesh · Delayed Price · Currency is BDT

219.30

+14.20 (6.92%)

At close: Nov 4, 2026

Market Cap	4.46B -51.4%
Revenue (ttm)	647.55M -4.1%
Net Income	35.51M -13.9%
EPS	1.74 -13.9%
Shares Out	20.36M
PE Ratio	125.73
Forward PE	n/a
Dividend	2.00 (0.91%)
Ex-Dividend Date	Dec 2, 2025

Volume	202,748
Open	n/a
Previous Close	205.10
Day's Range	204.90 - 223.00
52-Week Range	159.00 - 460.40
Beta	-1.63
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 12, 2026

About Orion Infusion

Orion Infusion Limited manufactures and sells large volume parenteral and other lifesaving injectable products in Bangladesh. The company offers I.V. rehydration, electrolyte, and acidosis solutions; ranitidine I.V. infusion; anti-microbial products; metronidazole I.V; pure steam generated fluids; and amino acids solution. It also provides sterile and nonpyrogenic solution, such as Dextrolac, Dianak, Hartman, Manisol, Plasmasol, and Proliv; hypertonic solution, including Dextrosal, Electrodex-10, Fructose – 10, Orlev, Ortac; Dextropac, an isoto... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 1983

Employees 563

Stock Exchange Dhaka Stock Exchange

Ticker Symbol ORIONINFU

Full Company Profile

Financial Performance

In fiscal year 2025, Orion Infusion's revenue was 664.92 million, a decrease of -19.64% compared to the previous year's 827.42 million. Earnings were 35.02 million, a decrease of -17.27%.

Financial Statements